How many 8-K filings has Rigel Pharmaceuticals Inc filed?

Rigel Pharmaceuticals Inc (RIGL) has 21 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Rigel Pharmaceuticals Inc 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Rigel Pharmaceuticals Inc 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Rigel Pharmaceuticals Inc (RIGL) — 8-K Filings

All 8-K filings from Rigel Pharmaceuticals Inc. Browse 21 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (21)

Rigel Pharmaceuticals Files 8-K Report — Dec 10, 2025 Risk: low
On December 7, 2025, Rigel Pharmaceuticals, Inc. filed an 8-K report to disclose other events and financial statements/exhibits. The filing was made on December
Rigel Pharmaceuticals Files 8-K on Financials — Aug 5, 2025 Risk: low
Rigel Pharmaceuticals, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
Rigel Pharmaceuticals Announces Board and Compensation Changes — May 23, 2025 Risk: medium
Rigel Pharmaceuticals, Inc. announced on May 22, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departu
Rigel Pharmaceuticals Files 8-K on Financials — May 6, 2025 Risk: low
Rigel Pharmaceuticals, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
Rigel Pharmaceuticals Files 8-K — Mar 27, 2025 Risk: low
On March 27, 2025, Rigel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specif
Rigel Pharmaceuticals Announces Board and Executive Changes — Mar 10, 2025 Risk: medium
Rigel Pharmaceuticals, Inc. announced on March 6, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depart
Rigel Pharmaceuticals Files 8-K on Financials — Mar 4, 2025 Risk: low
Rigel Pharmaceuticals, Inc. filed an 8-K on March 4, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
Rigel Pharmaceuticals Files 8-K Update — Jan 13, 2025 Risk: low
Rigel Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also inc
Rigel Pharmaceuticals Files 8-K Report — Dec 9, 2024 Risk: low
On December 9, 2024, Rigel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine upda
Rigel Pharmaceuticals Files 8-K on Financials — Nov 7, 2024 Risk: low
Rigel Pharmaceuticals, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial state
Rigel Pharmaceuticals Appoints New Chief Medical Officer — Sep 19, 2024 Risk: medium
Rigel Pharmaceuticals, Inc. announced on September 16, 2024, the appointment of Dr. V. Michael B. B. Castro as Chief Medical Officer. Dr. Castro previously serv
Rigel Pharmaceuticals Signs Material Definitive Agreement — Sep 3, 2024 Risk: medium
On September 3, 2024, Rigel Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement,
Rigel Pharmaceuticals Files 8-K on Financials — Aug 6, 2024 Risk: low
Rigel Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
Rigel Pharmaceuticals Files 8-K on Security Holder Rights — Jun 27, 2024 Risk: low
On June 27, 2024, Rigel Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to the rights of security holders and amendments to its artic
Rigel Pharmaceuticals Files 8-K — Jun 25, 2024 Risk: low
On June 25, 2024, Rigel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating a r
Rigel Pharmaceuticals Elects New Directors, Approves Compensatory Plans — May 29, 2024 Risk: low
Rigel Pharmaceuticals, Inc. announced on May 24, 2024, the election of Dr. David J. Earp and Ms. Sarah E. Kelly to its Board of Directors. The company also disc
Rigel Pharmaceuticals Files 8-K on Financials — May 7, 2024 Risk: low
Rigel Pharmaceuticals, Inc. filed an 8-K on May 7, 2024, to report on its results of operations and financial condition. The filing includes financial statement
Rigel Pharmaceuticals Amends Credit Agreement — Apr 12, 2024 Risk: low
On April 11, 2024, Rigel Pharmaceuticals, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to its Credit and Security Agreemen
Rigel Pharmaceuticals Files 8-K on Financials — Mar 5, 2024 Risk: medium
On March 5, 2024, Rigel Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing provides updates on the company's f
Rigel Pharma Reports Material Agreement & Asset Disposition — Feb 22, 2024 Risk: medium
Rigel Pharmaceuticals, Inc. filed an 8-K on February 22, 2024, reporting an entry into a material definitive agreement and the completion of an acquisition or d
RIGEL PHARMACEUTICALS 8-K: Financial Condition & Other Events Update — Jan 8, 2024
Rigel Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on 'Results of Operations and Financial Condition' and 'Other Events.' This filing indica

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX